Mindray seals $35.5M deal for Dragonbio's orthopedics implant line

Six weeks after the initial announcement, Chinese device giant Mindray Medical ($MR) has completed its $35.5 million bid to buy Wuhan Dragonbio Surgical Implant Co.'s orthopedics business. Dragonbio makes spine, joint, and trauma-related surgical orthopedics implants. The space represents a major growth area for Mindray and others. Frost & Sullivan estimated, for example, that the Chinese orthopedics market was worth $1.1 billion in 2010. Add to that a projected 18% annual growth rate, and Mindray will be off and running. Release

Suggested Articles

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.

CMR Surgical will have a new CEO at the top of the year, as it kicks off the global launch of its modular Versius system while awaiting FDA approval.

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.